NASDAQ
$6.20
(0.91%)
Subscribe to get
AI Score
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to...
The stock of Regeneron Pharmaceuticals, Inc (REGN) has gone down by -5.50% for the week, with a -5.21% drop in the past month and a -31.80% drop in the past quarter. The volatility ratio for ...
Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wiping out about $9 billion of market value.
HB Wealth Management LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 8.2% in the 4th quarter, HoldingsChannel.com reports. The institutional ...
Aaron Wealth Advisors LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 22.4% in the 4th quarter, according to its most recent disclosure with the Securities ...
The company has collaborated with Regeneron Pharmaceuticals REGN for the development of nex-z. Nex-z...
SAN DIEGO, Jan. 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, inclusive
NEW YORK, Jan. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN PR Newswire ...